2026-10-09 12:38:00 UTC#438316duplicateconfirmednews
ARCT stock news
ARCT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-09 12:27:48 UTC#438290newconfirmednews
Leerink Partners maintains Outperform rating on Arcturus Therapeutics, sets $19 price target
2026-09-29 06:14:21 UTC#382026newconfirmednews
Arctic Minerals reports maiden drilling results at Hennes Bay project with up to 3.18% copper equivalent
2026-09-24 15:56:00 UTC#363890duplicateconfirmednews
Citigroup upgrades Arcturus Therapeutics (ARCT) to Buy from Neutral
2026-09-24 14:26:38 UTC#363250newconfirmednews
Citi upgrades Arcturus Therapeutics to Buy following positive mid-stage liver disease drug trial data
2026-09-24 09:49:00 UTC#361301newconfirmednews
BTIG maintains Buy rating on Arcturus Therapeutics, cuts price target to $20 from $23
2026-09-23 23:52:51 UTC#359238duplicateconfirmednews
Arcturus Therapeutics reports positive Phase 2 data for ARCT-810 and LUNAR 2.0 platform progress
quartrimportance 0.30trust 0.50Arcturus Therapeutics Inc. +0.60ARCT-810 +0.60LUNAR 2.0 +0.50+2 entities
2026-09-23 22:45:21 UTC#359011updateconfirmednews
Arcturus Therapeutics details LUNAR 2.0 performance gains and FDA support for ARCT-2601 integration
quartrimportance 0.50trust 0.70Arcturus Therapeutics Inc. +0.60LUNAR 2.0 +0.50ARCT-810 +0.50+2 entities
2026-09-23 22:04:06 UTC#358896duplicateconfirmednews
Arcturus Therapeutics reports positive Phase 2 trial results for ARCT-810 in OTC deficiency
2026-09-23 20:29:00 UTC#358418duplicateconfirmednews
Arcturus Therapeutics to Acquire myNEO, Reports Positive Phase 2 Data for ARCT-810
dow_jonesimportance 0.40trust 0.80Arcturus Therapeutics Holdings Inc. +0.40myNEO +0.30ARCT-810 +0.40+2 entities
2026-09-23 20:07:00 UTC#358259updateconfirmednews
Arcturus Therapeutics (ARCT) expects to close acquisition of myNEO in October 2026
2026-09-23 20:07:00 UTC#358258duplicateconfirmednews
Arcturus Therapeutics to acquire AI discovery firm myNEO to enhance mRNA platform capabilities
2026-09-23 20:01:00 UTC#358165updateconfirmednews
Arcturus Therapeutics reports positive interim ARCT-810 Phase 2 data, unveils LUNAR 2.0 and to acquire myNEO
tradingviewimportance 0.50trust 0.70Arcturus Therapeutics Holdings Inc. +0.50myNEO +0.30ARCT-810 +0.40+2 entities
2026-09-23 14:04:37 UTC#356039newconfirmednews
Arcturus Therapeutics to present Phase 2 data for ARCT-810 in OTC deficiency and mRNA platform update
quartrimportance 0.40trust 0.60Arcturus Therapeutics Holdings Inc. +0.30ARCT-810 +0.30Ornithine Transcarbamylase Deficiency +0.30
2026-09-15 17:22:12 UTC#315799duplicateconfirmednews
Arcturus Therapeutics (ARCT) reiterates upcoming Phase II OTC deficiency data and pivotal CF program decision
2026-09-15 16:27:05 UTC#315435newconfirmedanalysis
Arcturus Therapeutics (ARCT) eyes Q4 pivotal CF program decision and phase II OTC deficiency data readout
2026-09-15 07:08:32 UTC#312100newconfirmednews
Arctic Minerals (ARCT) advances copper projects in Sweden and Norway with drilling results expected
2026-09-10 16:17:58 UTC#293643newconfirmednews
Arcturus Therapeutics (ARCT) expects clinical data readouts for liver and lung mRNA programs in next 6-12 months
2026-08-25 10:13:01 UTC#216651newconfirmednews
Arcturus Therapeutics to present ARCT-810 mRNA therapy data for OTC deficiency at 2026 SSIM Symposium
tradingviewimportance 0.30trust 0.90Arcturus Therapeutics, Inc. +0.10ARCT-810 +0.20Ornithine Transcarbamylase Deficiency 0+1 entities
2026-08-25 06:45:48 UTC#215869newconfirmednews